FTC still going after ephedra
This article was originally published in The Tan Sheet
Executive Summary
Three related supplement companies have been engaged in deceptive advertising practices, according to a Nov. 10 complaint filed by FTC. The defendants are cited for claiming Thermalean combines the weight-loss benefits of three different prescription drugs and Lipodrene has been clinically proven to cause substantial and safe weight loss, FTC announces Nov. 30. Both products contained ephedra, but have not been marketed or sold since FDA banned the botanical earlier this year. Four of the defendants - Jared Wheat, Hi-Tech Pharmaceuticals, National Urological Group and National Institute for Clinical Weight Loss - were named in an FDA consent decree in October 2003 that barred defendants from selling certain erectile dysfunction and obesity supplements (1"The Tan Sheet" Oct. 13, 2003, p. 4)...
You may also be interested in...
Dietary Supplement Obesity, Erectile Dysfunction Claims Barred By Court
An FDA consent decree barring the sale of dietary supplements purporting to treat obesity and erectile dysfunction follows repeated warnings to the marketers of the products, the agency announced Oct. 8
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.